Alarmingly low awareness of urology across Europe

September 24, 2018

Arnhem (The Netherlands), 24 September 2018 - Public awareness of urological conditions is alarmingly low throughout Europe. Results of a new international survey1 of more than 2,500 responders from 5 countries show that women know more about men's health issues than men do, men have poor knowledge of key urological symptoms and don't take early signs of potentially life-threatening urological conditions seriously.

The low level of awareness indicated by the survey is of particular concern as urological conditions are on a rise due to the ageing European population. Prevention and early diagnosis are crucial to save lives and to control increasing costs.

Fundamental Lack of Knowledge of Urology

Responses showed that urology as a medical speciality still has a long way to go to reach general awareness: 40% of respondents were unable to identify what a urologist does, 10% stated that they had never even heard of a urologist and almost 15% believe that a urologist treats disorders of the skeletal, nervous or circulatory systems.

"The results of our latest survey clearly demonstrate that people are ill-informed when it comes to urological conditions. Men in particular have less knowledge than women and turn a blind eye to symptoms and early diagnosis" comments Prof. Hein Van Poppel, urologist and Adjunct Secretary General of the EAU. "Persuading men to take their health seriously presents a serious challenge. They need to have a better understanding of the risk and symptoms of their conditions. They should be encouraged to seek support from a medical professional if they suspect anything unusual."

The Prostate Remains a Mystery to Many Men

Every year, almost 450,000 men across the continent will be diagnosed with prostate cancer, leading to 92,000 deaths in Europe2. Despite prostate cancer being the most common cancer in males throughout Europe, three quarters of men admitted that they have limited knowledge of its symptoms. Men are, in fact, more confident in recognising the symptoms of breast cancer (31%) than they are of prostate cancer (27%).

In addition to the low awareness of prostate cancer symptoms, just 1 in 4 respondents could correctly identify the location of the prostate and surprisingly, a higher proportion of women (28%) were able to identify the location of the prostate than males (22%). Worryingly, 54% of men believe that women have prostates.

Erectile Dysfunction and Incontinence Still Taboos

Erectile dysfunction (ED) prevalence in Europe is estimated at 50%3 of the sexually active men of 50 years and older. However, the topic remains a taboo leading to misunderstanding and ignorance. 75% of the respondents were not aware of the numbers of men that suffer from erectile dysfunction in their country. Similarly, 85% were unaware of the amount of people in their country that suffer from urinary tract issues.

"Men's health issues involve partners too", says Prof. Van Poppel. "Women are more used to checking their bodies. They should encourage men to do the same and discuss their health more in detail. Women should actively participate in conversations with their male partners and doctors."

International Differences in Testicular Cancer Knowledge

Testicular cancer is the most common type of cancer to affect younger men. However, survey results stated that only 18% of male respondents knew that men aged 16 to 44 years have the highest risk. Whilst knowledge was found to be low throughout Europe, there were stark differences; only 10% of the respondents from Spain know the at-risk age group compared to 27% in the UK.

Symptom awareness was also low with 70% of men lacking confidence in recognising the symptoms of testicular cancer, which may include a swelling or lump in one of the testicles and a dull ache or sharp pain in the testicles or scrotum.

Significant Delays in Visiting the Doctor

Symptom awareness is recognised as a leading factor in the early diagnosis of urological conditions. The majority of deaths in male cancers occur because most men do not address their conditions in time. Despite this, they continue to ignore their symptoms and delay seeing their doctors.

The survey reveals that 43% of people would not go to their doctor straight away if they notice blood in their urine; 23% would wait longer than a month if they suffered a frequent urge to urinate; 28% would wait for more than a week if they suffered burning or pain during urination; and only 17% of people surveyed associate pain in their lower abdomen with a serious problem.

Professor of urology and Executive Member for Communications at the EAU, Manfred Wirth adds "Urological diseases are extremely common; they cause a lot of discomfort and at times, can be life-threatening. It's time for Europe to change its attitude towards urology and invest in educational campaigns to increase urological knowledge and to break taboos."
-end-


European Association of Urology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.